scholarly journals Humoral and cellular immune correlates of protection against bubonic plague by a live Yersinia pseudotuberculosis vaccine

Vaccine ◽  
2019 ◽  
Vol 37 (1) ◽  
pp. 123-129 ◽  
Author(s):  
Christian E. Demeure ◽  
Anne Derbise ◽  
Chloé Guillas ◽  
Christiane Gerke ◽  
Simon Cauchemez ◽  
...  
2013 ◽  
Vol 19 (10) ◽  
pp. 1305-1312 ◽  
Author(s):  
Saranya Sridhar ◽  
Shaima Begom ◽  
Alison Bermingham ◽  
Katja Hoschler ◽  
Walt Adamson ◽  
...  

2017 ◽  
Vol 66 (4) ◽  
pp. 586-593 ◽  
Author(s):  
Aida Valmaseda ◽  
Eusebio Macete ◽  
Augusto Nhabomba ◽  
Caterina Guinovart ◽  
Pedro Aide ◽  
...  

2012 ◽  
Vol 54 (11) ◽  
pp. 1615-1617 ◽  
Author(s):  
S. A. Plotkin ◽  
P. B. Gilbert

Vaccines ◽  
2020 ◽  
Vol 8 (2) ◽  
pp. 264
Author(s):  
Wolfgang W. Leitner ◽  
Megan Haraway ◽  
Tony Pierson ◽  
Elke S. Bergmann-Leitner

The quest for immune correlates of protection continues to slow vaccine development. To date, only vaccine-induced antibodies have been confirmed as direct immune correlates of protection against a plethora of pathogens. Vaccine immunologists, however, have learned through extensive characterizations of humoral responses that the quantitative assessment of antibody responses alone often fails to correlate with protective immunity or vaccine efficacy. Despite these limitations, the simple measurement of post-vaccination antibody titers remains the most widely used approaches for vaccine evaluation. Developing and performing functional assays to assess the biological activity of pathogen-specific responses continues to gain momentum; integrating serological assessments with functional data will ultimately result in the identification of mechanisms that contribute to protective immunity and will guide vaccine development. One of these functional readouts is phagocytosis of antigenic material tagged by immune molecules such as antibodies and/or complement components. This review summarizes our current understanding of how phagocytosis contributes to immune defense against pathogens, the pathways involved, and defense mechanisms that pathogens have evolved to deal with the threat of phagocytic removal and destruction of pathogens.


2017 ◽  
Vol 7 (1) ◽  
Author(s):  
Sook-San Wong ◽  
Susu Duan ◽  
Jennifer DeBeauchamp ◽  
Mark Zanin ◽  
Lisa Kercher ◽  
...  

2016 ◽  
Vol 23 (3) ◽  
pp. 228-235 ◽  
Author(s):  
Andrew J. Dunning ◽  
Carlos A. DiazGranados ◽  
Timothy Voloshen ◽  
Branda Hu ◽  
Victoria A. Landolfi ◽  
...  

ABSTRACTAlthough a number of studies have investigated and quantified immune correlates of protection against influenza in adults and children, data on immune protection in the elderly are sparse. A recent vaccine efficacy trial comparing standard-dose with high-dose inactivated influenza vaccine in persons 65 years of age and older provided the opportunity to examine the relationship between values of three immunologic assays and protection against community-acquired A/H3N2 influenza illness. The high-dose vaccine induced significantly higher antibody titers than the standard-dose vaccine for all assays. For the hemagglutination inhibition assay, a titer of 40 was found to correspond with 50% protection when the assay virus was antigenically well matched to the circulating virus—the same titer as is generally recognized for 50% protection in younger adults. A dramatically higher titer was required for 50% protection when the assay virus was a poor match to the circulating virus. With the well-matched virus, some protection was seen at the lowest titers; with the poorly matched virus, high levels of protection were not achieved even at the highest titers. Strong associations were also seen between virus neutralization test titers and protection, but reliable estimates for 50% protection were not obtained. An association was seen between titers of an enzyme-linked lectin assay for antineuraminidase N2 antibodies and protection; in particular, the proportion of treatment effect explained by assay titer in models that included both this assay and one of the other assays was consistently higher than in models that included either assay alone. (This study has been registered at ClinicalTrials.gov under registration no. NCT01427309.)


Sign in / Sign up

Export Citation Format

Share Document